AGREED!! Check out my stickied post from back in March...
The company has a limited financial ability.
They cant get financing because they arent current, which they are currently attempting to get current.
Getting current will give them options for financing.
What i really like about this company is that they arent wasting money by paying for literally anything at this moment.
No employees (Limited Basis Chris Lowe)
No office space
All board members are working/studying at other facilities: https://www.investing.businessweek.wallst.com/research/stocks/people/board.asp?ticker=NSPX
They own the drug Patents.
The are letting others help in the study and advancement through University/Government Grants. Anything they come up with is owned under the Patents
They are not throwing money away.
No money wasted on PR's.
They only information coming out about their Orphan Status DRUG $MIPSAGARGIN is PUBLISHED via FACTUAL PIER REVIEWED Scientific Communities.
When they solve the Synthesized Mipsagargin hold up and are able to commercially provide a viable supply chain that is going to be the catalyst for PHASE 3 Clinical Trials!